BioSpace News Archive

This was an essential step in recertifying under the ISO standard with annual surveillance audits for the next two years.

FDA grants a Priority Review based on Phase 3 ATTR-ACT study findings in ATTR-CM

ORHub, Inc. (OTC: ORHB) (the “Company” or “ORHub”), a SaaS-based healthcare data analytics company focused on the business of surgery to improve the profitability of hospitals, ambulatory surgery centers (ASCs) and health systems today announces that ORHub has signed a new contract with Metropolitan Surgery Center in New Jersey.

Beyond Limits, a leading artificial intelligence engineering company, has announced the formation of a healthcare advisory board composed of prominent physicians and healthcare executives from world-renowned medical clinics and companies.

The Quell Foundation continues to impact lives across the country, raising over one million dollars in 2018 toward their mission to remove the stigma of mental health and to fund the next generation of mental health care professionals.

Accident survivors, medical professionals, and state policymakers share their perspectives on the value of this unique system.

Quantzig, a leading analytics advisory firm that delivers customized analytics solutions, has announced the completion of their article on the best strategies for leveraging patient journey mapping to improve patient experience.

Heffernan Insurance Brokers, one of the largest full-service, independent insurance brokerage firms in the United States, now offers a comprehensive insurance program specifically for retail pharmacies.

The Board of Directors of the Plasma Protein Therapeutics Association (PPTA) announced today that Amy Efantis will be its next President and Chief Executive Officer effective January 16, 2019.

INVO Bioscience, Inc. (OTCQB: IVOB), developers of the INVOcell intravaginal culture (IVC) system, and Ferring Pharmaceuticals, a specialty biopharmaceutical group committed to helping people around the world build families and live better lives, announced today the closing of the previously announced exclusive U.S. commercialization rights agreement for INVOcell.